Affymetrix Shares Decline on Downgrade from JP Morgan | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of microarray firm Affymetrix tumbled about 7 percent after investment firm JP Morgan downgraded the company to "underweight" from "neutral."

In mid-afternoon trading, shares of the Santa Clara, Calif., firm's stock were down to $4.71 from $5.05 at the close of the market on Monday. More than 1.3 million shares had been traded, up from an average daily volume of less than 900,000 shares during the past three months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.